Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter study
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
and progression of diabetic complications and antagonists of renin-angiotensin system and amlodipine have been reported previously to reduce oxidative stress. In this study, we compared the changes in oxidative stress markers after valsartan and amlodipine treatment in type 2 diabetic patients with hypertension and compared the changes in metabolic parameters. Methods: Type 2 diabetic subjects with hypertension 30 to 80 years of age who were not taking antihypertensive drugs were randomized into either valsartan (n = 33) or amlodipine (n = 35) groups and treated for 24 weeks. We measured serum nitrotyrosine levels as an oxidative stress marker. Metabolic parameters including serum glucose, insulin, lipid profile, and urine albumin and creatinine were also measured. Results: After 24 weeks of valsartan or amlodipine treatment, systolic and diastolic blood pressure decreased, with no significant difference between the groups. Both groups showed a decrease in serum nitrotyrosine (7.74 ± 7.30 nmol/L vs. 3.95 ± 4.07 nmol/L in the valsartan group and 8.37 ± 8.75 nmol/L vs. 2.68 ± 2.23 nmol/L in the amlodipine group) with no significant difference between the groups. Other parameters including glucose, lipid profile, albumin-to-creatinine ratio, and homeostasis model assessment of insulin resistance showed no significant differences before and after treatment in either group. Conclusions: Valsartan and amlodipine reduced the oxidative stress marker in type 2 diabetic patients with hypertension.
Abstract
and progression of diabetic complications and antagonists of renin-angiotensin system and amlodipine have been reported previously to reduce oxidative stress. In this study, we compared the changes in oxidative stress markers after valsartan and amlodipine treatment in type 2 diabetic patients with hypertension and compared the changes in metabolic parameters. Methods: Type 2 diabetic subjects with hypertension 30 to 80 years of age who were not taking antihypertensive drugs were randomized into either valsartan (n = 33) or amlodipine (n = 35) groups and treated for 24 weeks. We measured serum nitrotyrosine levels as an oxidative stress marker. Metabolic parameters including serum glucose, insulin, lipid profile, and urine albumin and creatinine were also measured. Results: After 24 weeks of valsartan or amlodipine treatment, systolic and diastolic blood pressure decreased, with no significant difference between the groups. Both groups showed a decrease in serum nitrotyrosine (7.74 ± 7.30 nmol/L vs. 3.95 ± 4.07 nmol/L in the valsartan group and 8.37 ± 8.75 nmol/L vs. 2.68 ± 2.23 nmol/L in the amlodipine group) with no significant difference between the groups. Other parameters including glucose, lipid profile, albumin-to-creatinine ratio, and homeostasis model assessment of insulin resistance showed no significant differences before and after treatment in either group. Conclusions: Valsartan and amlodipine reduced the oxidative stress marker in type 2 diabetic patients with hypertension.
참고문헌 (33)
- Emerging Risk Factors Collaboration, "Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies", Lancet, 375, pp.2215~2222 (2010)
- Hu G, "Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease", Eur Heart J, 28, pp.3059~3066 (2007)
- Hsueh WA, "Renin-angiotensin-aldosterone system in diabetes and hypertension", J Clin Hypertens (Greenwich), 13, pp.224~237 (2011)
- Araki E, "Oxidative stress: a cause and therapeutic target of diabetic complications", J Diabetes Investig, 1, pp.90~96 (2010)
- Giacco F, "Oxidative stress and diabetic complications", Circ Res, 107, pp.1058~1070 (2010)
- Dikalov SI, "Role of mitochondrial oxidative stress in hypertension", Am J Physiol Heart Circ Physiol, 305, pp.H1417~H1427 (2013)
- Chabrashvili T, "Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression", Am J Physiol Regul Integr Comp Physiol, 285, pp.R117~R124 (2003)
- Hornig B, "Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase", Circulation, 103, pp.799~805 (2001)
- Fliser D, "Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation", Circulation, 110, pp.1103~1107 (2004)
- Mason RP., "Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine:review of the evidence", Atherosclerosis, 165, pp.191~199 (2002)
- Aksnes TA, "Treatment of hypertension in diabetes: what is the best therapeutic option?", Expert Rev Cardiovasc Ther, 10, pp.727~734 (2012)
- Zhou MS, "Thiazide diuretics, endothelial function, and vascular oxidative stress", J Hypertens, 26, pp.494~500 (2008)
- Friedewald WT, "Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge", Clin Chem, 18, pp.499~502 (1972)
- Forstermann U., "Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies", Nat Clin Pract Cardiovasc Med, 5, pp.338~349 (2008)
- Ho E, "Biological markers of oxidative stress: applications to cardiovascular research and practice", Redox Biol, 1, pp.483~491 (2013)
- Dalle-Donne I, "Biomarkers of oxidative damage in human disease", Clin Chem, 52, pp.601~623 (2006)
- Brasier AR, "Vascular inflammation and the renin-angiotensin system", Arterioscler Thromb Vasc Biol, 22, pp.1257~1266 (2002)
- Shimada K, "Olmesartan, a novel angiotensin II type 1receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production", Nutr Metab Cardiovasc Dis, 21, pp.672~678 (2011)
- American Diabetes Association., "8. Cardiovascular disease and risk management", Diabetes Care, 39(Suppl 1), pp.S60~S71 (2016)
- Dohi Y, "Candesartan reduces oxidative stress and inflammation in patients with essential hypertension", Hypertens Res, 26, pp.691~697 (2003)
- Yung LM, "Inhibition of renin-angiotensin system reverses endothelial dysfunction and oxidative stress in estrogen deficient rats", PLoS One, 6, pp.e17437~ (2011)
- Wu B, "Valsartan attenuates oxidative stress and NF-κB activation and reduces myocardial apoptosis after ischemia and reperfusion", Eur J Pharmacol, 705, pp.140~147 (2013)
- Zhou G, "Valsartan slows the progression of diabetic nephropathy in db", db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation, 2014, pp.126, 707~720
- Mason RP, "Novel vascular biology of third-generation L-type calcium channel antagonists:ancillary actions of amlodipine", Arterioscler Thromb Vasc Biol, 23, pp.2155~2163 (2003)
- 박창규, "Is amlodipine more cardioprotective than other antihypertensive drug classes?", The Korean Journal of Internal Medicine, 29(3), pp.301~304 (2014), 대한내과학회[DOI]
- Takebayashi K, "The effect of amlodipine on oxidative stress in patients with type 2 diabetes", SRX Med, 2010, pp.326840~ (2010)
- Julius S, "Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial", Lancet, 363, pp.2022~2031 (2004)
- Wang JG, "Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials", J Am Soc Hypertens, 8, pp.340~349 (2014)
- Yasunari K, "Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy", J Am Coll Cardiol, 43, pp.2116~2123 (2004)
- Naya M, "Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients", J Am Coll Cardiol, 50, pp.1144~1149 (2007)
- Hirooka Y, "Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension", Clin Exp Hypertens, 30, pp.267~276 (2008)
- Aslam S, "Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis", Kidney Int, 70, pp.2109~2115 (2006)
- Weber MA, "Cardiovascular events during differing hypertension therapies in patients with diabetes", J Am Coll Cardiol, 56, pp.77~85 (2010)